Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 33

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 33
---
 including from this offering, or convertible debt
securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that
adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available,
may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends. In addition, if we issue secured debt securities, the holders of the debt would
have a claim to our assets that would be senior to the rights of stockholders until the debt is paid. Interest on these debt securities
would increase costs and negatively impact operating results. If the issuance of new securities results in diminished rights to holders
of our common stock, the market price of our common stock could be negatively impacted.

If we raise additional
funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be
required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that may not be
favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third
parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization
efforts or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and
market ourselves.

<div align='center'>S-19</div>

The common stock offered hereby will be sold in “at the market offerings,” and investors who buy shares at different times will likely pay different prices.

Investors who purchase shares
in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results.
We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or
maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than
the prices they paid.

Because the offering price of our common stock may be substantially higher than the net tangible book value per share of our outstanding common stock, new investors may experience immediate and substantial dilution.

The public offering price of
our common stock in this offering may be substantially higher than the net tangible book value per share of our common stock outstanding
prior to this offering based on the total value of our tangible assets less our